Safety and Feasibility of Accelerated Pembrolizumab and Nivolumab Infusions: A Quality Improvement Initiative (AVAHO 2026) - Oct 11, 2026 - Abstract #42; Pres time: Sep 12, 2026; 11:15 AM - 12:15 PM; "Forty-two patients (average age 74; ECOG 2; 41 male) received 60 accelerated infusions. Most received pembrolizumab (n=39) and three received nivolumab. A single IRR occurred (1.66%), presenting as asymptomatic grade 3 hypertension requiring no intervention; subsequent accelerated infusion was tolerated."
Clinical • Hypertension
|